Skip to content

A randomised, double-blind, placebo-parallel controlled clinical study on the treatment of Hashimoto's thyroiditis with liver-depression and spleen-deficiency and blood stasis in the veins and channels by Jiayankangtai prescription.

A randomised, double-blind, placebo-parallel controlled clinical study on the treatment of Hashimoto's thyroiditis with liver-depression and spleen-deficiency and blood stasis in the veins and channels by Jiayankangtai prescription.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079341
Enrollment
Unknown
Registered
2024-01-01
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto's thyroiditis

Interventions

experimental group:Jiayankangtai granules, take with lukewarm water, 1 sachet at a time, 2 times a day, after meals.
control group:Jiayankangtai granules analogue, take with lukewarm water, 1 sachet at a time, 2 times a day, after meals.

Sponsors

Dongfang Hospital Beijing University of Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Meets western medical diagnostic criteria for Hashimoto's thyroiditis; (2)Meets the Chinese medicine diagnostic criteria of liver depression, spleen deficiency and blood stasis obstruction syndrome; (3Age18- 65 years old and gender is not limited; (4)Informed consent, voluntary testing, informed consent process in accordance with GCP.

Exclusion criteria

Exclusion criteria: (1)Western clinical diagnosis of hypothyroidism, or subclinical hypothyroidism with TSH >10IU/ml; (2)In the last 6 months ,who with severe bleeding disorders, peptic ulcer, grade 3 hypertension, unstable angina, severe arrhythmia, cardiopulmonary insufficiency, pacemaker or stent implantation, history of myocardial infarction , or hepatic or renal insufficiency, ALT, AST higher than 2 times the upper limit of normal, or Cr higher than the upper limit of normal (higher than 84 umol/L for females and higher than 104 umol/L for males) ; (3) Those who have combined other medications for Hashimoto's thyroiditis (selenium yeast tablets, levothyroxine sodium tablets, glucocorticoids, vitamin D preparations) within the last 3 months; (4)Patients with malignant tumours; (5)Women who are pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frame
Serum TPOAb antibody titre level test;

Secondary

MeasureTime frame
Serum TgAb antibody titre level test;TCM symptom score;

Countries

China

Contacts

Public ContactWenming Yi

Dongfang Hospital Beijing University of Chinese medicine

ywmabc33@163.com+86 135 5243 9907

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026